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influence the outcome of treatment. The objective was to assess patient preferences 
on treatments for ED by applying Conjoint Analysis. Methods: Seven attributes 
were selected through a literature review and a consultation with 25 patients treated 
of ED and 5 experts: effectiveness (E), rapidity of onset (R), duration of effect (D), 
adverse events (AE), methods of administration (MA), price (P) and interaction with 
alcohol and food (I). 3 groups of scenarios were selected using “Orthogonal Design”: 
Phase 1, 9 scenarios with 4 attributes (R, D, MA, I); Phase 2, 16 scenarios with the 7 
attributes; Phase 3, 9 scenarios with 4 attributes (E, MA, P, I). It was applied the “Order 
of simulated preference” method by using cards with symbols and text. Interactions 
of age, comorbidity and frequency of sexual intercourses with preferences were 
studied. Results: The set of 16 scenarios was very difficult for patients. A total 
of 314 patients participated in Phase 1, 99 in Phase 2 and 178 in Phase 3. Order of 
preferred attributes: Phase 1: MA (57.99%), D (16.68%), I (14.57%) y R (10.76%); Phase 
2: MA (40.53%),E (21.98%), R (8.98%), P (8.11%), D (7.46%), AE (6.67%),I (6.25%); Phase 
3: MA (53.9%), I (22.45%), P (12.50%), E (11.14%). The preferred MA in the 3 phases 
was the orodispersible tablet with reference to pill and injectable. No statistically 
significant associations were found with age, comorbidity and frequency of sex-
ual intercourse. ConClusions: . Patients gave more importance to the attribute 
“method of administration” in any of the three phases performed. The preferred 
MA was orodispersible tablet over pill and injectable.
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objeCtives: The EQ-5D-3L descriptive classification defines a total of 243 health 
states which presents a problem when seeking to establish social preferences. As 
it would be challenging to value all 243 health states, a subset is chosen but the 
basis for this selection varies across national valuation studies. The aim of this 
study was to choose health states based on the most commonly found health states 
experienced by the Irish population. Methods: EQ-5D data from four different 
datasets were combined to determine what health states are prevalent in Ireland. 
Data from a general population study of health (SLAN), an over 70 population cohort, 
a rheumatoid arthritis and psoriatic arthritis cohort. The most commonly experi-
enced health states were determined and these were arranged on a 5 dimensional 
lattice. Health states were chosen using the Manhattan distance metric. Results: 
A total of 12,520 ratings of self-reported EQ-5D health states were included. Fifty 
two per cent of the cohort had perfect health (11111). Ninety five per cent of states 
include at least one ‘1’ and no ‘3’. 126/243 health states were not experienced in 
these datasets. The Manhattan distance between health states was measured. The 
imposition of such a metric facilitated the identification of clusters of states and 
associated centroids. Distance sampling was used to identify states within the clus-
ters. A simple random sampling strategy was also used across the lattice to ensure 
coverage of health states outside of the cluster ConClusions: Previous population 
preference elicitation studies have used theoretical approaches to health states 
elicitation, which could lead to health states being directly valued which are rarely 
experienced in the population. The approach presented here uses the information 
already known about the population, to inform choice of health states for population 
valuation of health using the EQ-5D.
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objeCtives: To describe HUI reference statistics available from clinical and general 
population health studies. Methods: Reviews of published literature, unpublished 
reports and corporate databases were used to identify summary statistics or data 
available for calculation of summary statistics. Published examples illustrate the use 
of HUI reference statistics for health-related quality of life (HRQL) scores to assess the 
health of patients relative to general populations and of general populations between 
countries. Results: Summary statistics of HRQL scores were compiled from pub-
lished clinical studies (n= 5), population health surveys (n= 6), or provided by investiga-
tors of individual studies (n= 3). Statistics from four sets of published results were used 
to identify health problems among patients treated for acute lymphoblastic leukemia 
in childhood in a recently published study. Results from the Joint Canada/US Survey of 
Health (JCUSH), conducted at the same time in both countries using the same survey 
methodology are presented here in brief. The mean HUI3 score in Canada (0.88) was 
slightly higher than in the US (0.87) (p< 0.05). However, the mean HUI3 score for those 
with less than a high school education in Canada (0.81) was much higher than the 
mean for the same group in the US (0.74) (p< 0.05). HUI Mark2 (HUI2) and HUI Mark3 
(HUI3) summary statistics by country, gender, race and age groups are presented in 
43 tables on the HUI web-site (www.healthutilities.com). ConClusions: The results 
highlight the usefulness of continuous preference-based measures of population 
health such as the HUI3. Population reference data enable international comparisons 
of population health and provide normative data with which to interpret results from 
clinical studies. The publicly available summary statistics of interval-scale preference-
based measures for the HRQL of reference populations provide valid, reliable and 
cost-effective results for clinical and general population studies.
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level dynamic Bayesian inhomogeneous Markov model with quarterly time-step 
was then developed to jointly describe prescriptions and outcomes over time 
in relation with adherence proxy using medication possession ratio, adjusting 
for patients demographics and seasonality. Internal and external validation was 
performed. Results: . Such Bayesian model could be fitted to the available data 
with different parameters informed by one or another data source. Treatment 
switches were associated with severity at the previous quarter while adherence 
was significantly improved when patients are switched and when they are less 
controlled in the previous quarter. Risk of exacerbations was depending on the 
control score and season at the present quarter and on the risk of exacerbation 
at the previous quarter. Control was significantly improved by a better adherence 
and to a lesser extent by a treatment escalation and improved severity at the previ-
ous quarter. ConClusions: This Bayesian dynamic model allowed quantifying 
the most important interactions between drug uses and effects on control and 
exacerbations over time, hence providing a powerful tool for real-world outcomes 
predictions in asthma patients.
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objeCtives: Large scale simulation models (e.g. Archimedes Model, MISCAN) are 
increasingly used to predict cost-effectiveness of medical interventions and to 
drive reimbursement decisions. These models are complex and involve hundreds 
of parameters and inputs. Quantification of parameter uncertainties using tradi-
tional sampling-based approaches (e.g., Monte Carlo sampling and its variants) can 
be prohibitively expensive for these models. Methods: We overcome the limita-
tions of traditional probabilistic sensitivity analysis through a 4-step process. First, 
we conduct a thorough survey of all parameters and their confidence intervals. 
Second, we use local sensitivity analysis to evaluate the effects of each parameter 
on the outcome of interest. Third, based on results from single-parameter sensitivity 
analysis, we rank and identify a group of parameters that have the largest effects 
on the outcome. We then employ response surface (RS) approximation methods 
to create a mathematical model of the model predictions for these parameters. 
We use Latin Hypercube sampling (LHS) to generate data points and multivariate 
adaptive regression splines (MARS) to build the response surface approximations. 
Fourth, we sample parameters from their joint distributions, and then use the con-
structed response surface to calculate the probability distribution of the predicted 
outcomes. Results: We apply the above methodology to quantify uncertainties 
in predictions of the Archimedes Model for effectiveness of colorectal cancer (CRC) 
screening by colonoscopy (COLO) and fecal immunological test (FIT). We started out 
with 200 parameters and identified 20 parameters that have significant influences 
on predicted effectiveness of CRC screening. We conclude that there is a 89% chance 
that COLO will save more life years FIT, after accounting for parameter uncertainties. 
Similarly we estimate that there is a 61% probability that FIT is more cost effective 
than colonoscopy. ConClusions: We have developed a robust and efficient meth-
odology for quantifying parameter uncertainties of large-scale simulation models 
used for cost-effectiveness analysis.
ReseaRCh on MethoDs – Patient-Reported outcomes studies
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objeCtives: EQ-5D catalogues have been developed and tested in US and UK. The 
current study aims to develop a Danish preference-based EQ-5D 3L scores cata-
logue for around a hundred of the most common monitored chronic conditions. The 
development is based on experiences from the US and UK, but adding new factors of 
importance such as health habits, BMI, social networks and stress. Methods: The 
marginal disutility estimates will be calculated using CLAD and OLS regression on a 
single source population from a random sample: the National Danish Health Survey 
Data from 2010 which is a self-administrated survey with approx. 38.000 respond-
ents age ≥ 16. The survey data is combined with data from national registers contain-
ing individual health data e.g. diagnosed chronic conditions during hospitalization, 
medication, use of hospitals as well as socio-economic data. The catalogue differs 
from UK and US catalogues’ by adding health habits information and by using ICD-
10 classifications from registers as well as it is based on Danish EQ-5D tariffs. The 
marginal disutility is calculated for each chronic condition controlling for age, gen-
der, ethnicity, income, education and comorbidity etc. Results: Marginal disutility 
estimates (EQ-5D) for around a hundred ICD-10 chronic conditions are presented 
and compared. It is expected that this new knowledge will contribute and qualify 
prioritization debate, when results are published and combined with knowledge of 
for example factors of importance and burden of disease in costs. ConClusions: 
The catalogue will provide scientist with an “off-the-shelf” tool for use in health eco-
nomic evaluations. Marginal disutilities estimates can be used to estimate QALY’s 
in CEA for a wide variety of conditions in Denmark.
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objeCtives: Phosphodiesterase type 5 inhibitors (PDE5i) for the treatment of erec-
tile dysfunction (ED) have similar pharmacologic profile. Patient preferences may 
